Main Menu

Video: The benefits of partnering with industry

Dr Igor Vivanco leads our Molecular Addictions team, which is working on a variety of projects that could be developed in collaboration with commercial partners.

Cancer cells can become dependent on certain signalling pathways, leaving them unable to survive without some specific oncogenic gene products. They can also become addicted to nutrients, such as glucose and glutamine.

Dr Vivanco’s team is studying these addictions in order to better understand them – and ultimately with the aim of discovering new therapeutic strategies that exploit these vulnerabilities.

In particular, Dr Vivanco’s team has been investigating the molecular basis of addiction to the PI3K signalling pathway, which is altered in the majority of human cancers.

Dr Vivanco has had significant experience in working with industry, and is open to new partnerships, particularly in discovering novel therapeutics, such as antibodies, for targeting these molecular addictions.

Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.

Watch

New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.

Watch

Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.

Watch

Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.

Watch

Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.

Watch

The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.

Watch

Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.